Pacira Biosciences (PCRX) Patent Misrepresentation Case

• $PCRX investors filed a lawsuit against Pacira Biosciences for misleading shareholders about Exparel's patent strength and protection against generics.

• On August 9, 2024, Pacira announced that the U.S. District Court invalidated its key Exparel patent, following this news, $PCRX stock dropped by 47.7%.

• $PCRX investors can join this case to be notified about potential recovery.

Case Details:

Between August 2, 2023, and August 8, 2024, Pacira assured investors that Exparel’s patents were strong and would protect the drug from generic competitors.

The company highlighted Exparel as its flagship product, accounting for 80% of Pacira’s revenue, and emphasized its plans for expanded usage and production.

However, on August 9, 2024, Pacira announced that its key Exparel patent had been invalidated, raising concerns about the strength of its other patents and the risk of generic competition.

Following the announcement, PCRX dropped by 47.7%.

Based on these events, $PCRX investors filed a lawsuit against Pacira Biosciences, claiming the company:

• It misled investors about the strength of Exparel’s patent protection and its ability to block generic competition.

• It overstated its ability to expand Exparel’s market dominance despite legal risks.

Investors believe Pacira misrepresented Exparel’s patent security and the associated risks, leading to significant financial losses when the patent was invalidated.